Abstract Search

ey0019.2-9 | Neonatal diabetes mellitus | ESPEYB19

2.9. SGLT2 inhibitors therapy protects glucotoxicity-induced [beta]-cell failure in a mouse model of human KATP-induced diabetes through mitigation of oxidative and ER stress

ZA Shyr , Z Yan , A Ustione , EM Egan , MS Remedi

PLoS One. 2022 Feb 18;17(2):e0258054. doi: 10.1371/journal.pone.0258054. PMID: 35180212.Brief Summary: This mouse model of diabetes describes how early administration of sodium glucose transporter 2 (SGLT2) inhibitors can protect pancreatic beta-cells from glucotoxicity damage. Early use of SGLT2 inhibitors can revert/prevent beta-cell failure in mice with diabetes due to KATP channel de...

0 shares

ey0019.2-10 | Neonatal diabetes mellitus | ESPEYB19

2.10. Genetic reduction of glucose metabolism preserves functional [beta]-cell mass in KATP-induced neonatal diabetes

Z Yan , M Fortunato , ZA Shyr , AL Clark , M Fuess , CG Nichols , MS Remedi

Diabetes. 2022 1;71(6):1233-1245. doi: 10.2337/db21-0992. PMID: 35294000.Brief Summary: This mouse model of diabetes tested the hypothesis that reducing the metabolic flux (rate of metabolism) in the beta cell can prevent beta-cell failure and preserve beta-cell mass. Reducing glucose metabolism may be a mechanism for preventing glucotoxicity-induced loss of functional beta-cell mass in diabetes. <...

0 shares

ESPE Yearbook of Paediatric Endocrinology

2.9. SGLT2 inhibitors therapy protects glucotoxicity-induced [beta]-cell failure in a mouse model of human KATP-induced diabetes through mitigation of oxidative and ER stress

2.10. Genetic reduction of glucose metabolism preserves functional [beta]-cell mass in KATP-induced neonatal diabetes

BiosciAbstracts